Objectives: Mutations in the b-subunit of RNA polymerase (RNAP), encoded by rpoB, are responsible for rifampicin resistance (Rif R There is a strong correlation between the magnitude of the fitness cost of a Rif R mutation in Salmonella Typhimurium or M. smegmatis and the frequency with which that mutation is associated with secondary (putative compensatory) mutations in RNAP of clinical MTB isolates.
Introduction
Rifampicin in an essential antibiotic in anti-TB treatment. 1 It binds bacterial RNA polymerase (RNAP) in the active site and causes the abortion of transcription when the transcript becomes two to three nucleotides in length. 2 Rifampicin resistance (Rif R ) is caused by mutations in the gene rpoB, which encodes the b-subunit of RNAP. In 96% of clinical Rif R Mycobacterium tuberculosis (MTB) isolates, point mutations, small duplications or small deletions have been reported in a stretch of 81 bp (amino acids 507 -534) of rpoB called cluster I or the Rif R -determining region (RRDR). 3 Additionally, Rif R mutations can be found in cluster N (amino acids 146 and 148), cluster II (amino acids 563 -574) and cluster III (amino acid 687). 4 Although a wide variety of Rif R mutations are known, only a small fraction of these mutations are responsible for the vast majority of clinical Rif R in MTB. 3, 5 To explain this bias, it has been suggested that Rif R mutations that are predominantly found in clinical MTB isolates have a low fitness cost, as has been shown to be the case with other chromosomal drug resistance-conferring mutations. 6, 7 The competitive fitness of drug-resistant MTB isolates has been measured to test this hypotheses, but so far only a very limited number of mutations have been tested and the results vary between different groups. 8 -10 One reason for this variation might be the fact that some of these measurements were conducted on spontaneously selected Rif R mutants without moving the mutation into an isogenic background. A pioneering study in 2010 provided the first experimental evidence for the presence of compensatory mutations in MTB using Mycobacterium smegmatis as a model to reconstruct the evolution of aminoglycoside resistance in an isogenic strain background. In this study we used Salmonella enterica as a model system to construct and subsequently characterize a set of 122 distinct Rif R mutations. We also tested a subset of these Rif R mutations isolated in M. smegmatis. Our aims were to: (i) create a library of isogenic strains with Rif R mutations; (ii) characterize the phenotypes of these mutations; and (iii) search for a correlation between the phenotypes of the Rif R mutations and their respective clinical frequency.
Materials and methods

Bacterial strains and growth conditions of Salmonella strains
Rif R Salmonella strains were made by oligonucleotide recombineering in Salmonella Typhimurium LT2 and Salmonella Saintpaul CDC B1606. 12 Rif R mutations were moved from Salmonella Typhimurium LT2 into Salmonella Typhimurium 14028s by P22 transduction. 13 Bacteria were grown at 378C in LB broth and on plates of LB broth medium solidified with 1.5% agar (Oxoid) (LA-plates). Rifampicin was added to media as required at 24 or 100 mg/L. Growth rates were measured using a Bioscreen C machine (Oy Growth Curves Ab Ltd). Overnight cultures were diluted 2000-fold in LB broth, LB broth+24 mg/L rifampicin or LB broth+100 mg/L rifampicin and 300 mL of the diluted culture was incubated at 378C with continuous shaking on honeycomb microtitre plates with OD readings at 5 min intervals. The doubling time was calculated from the increase in OD at 600 nm. Competitive fitness costs were determined using fluorescence-marked strains. Overnight cultures of WT strains with either YFP or BFP fluorescence markers were mixed in a 1: 1 ratio with isogenic Rif R mutants carrying the other fluorescence marker (where YFP stands for yellow fluorescent protein and BFP stands for blue fluorescent protein). Competition was performed by 1000-fold serial dilution every 24 h for 4 days. The ratio of competitors was determined before every passage using a fluorescenceactivated cell sorter (BD FacsAria). Competitive fitness costs were calculated as previously described.
14 Rifampicin MICs were determined using broth dilution. 13 Bacterial strains and growth conditions of M. smegmatis strains All strains are derived from M. smegmatis strain MC 2 155. Rif R mutations were spontaneously selected. Bacteria were grown at 378C in Middlebrook 7H9 broth supplemented with 10% Middlebrook OADC growth supplement, 0.5% glycerol and 0.05% Tween 80 or on 7H10 plates supplemented with 10% Middlebrook OADC growth supplement and 0.5% glycerol. Rifampicin was added to media at 25 mg/L. Growth rates were measured using a Bioscreen C machine (Oy Growth Curves Ab Ltd). Cultures that had been grown for two nights were diluted 100-fold in 7H9 medium and 300 mL of the diluted culture was incubated at 378C with continuous shaking in honeycomb microtitre plates, with OD readings at 10 min intervals. The doubling time was calculated from the increase in OD at 600 nm.
PCR amplification and DNA sequencing
Preparation of DNA was performed as previously described. 13 Primers for amplification and sequencing of rpoB are described in Table S1 (available as Supplementary data at JAC Online). DNA sequencing was carried out at Macrogen (Amsterdam, the Netherlands).
Analysis of clinical MTB data to determine the frequency of multiple Rif R mutations
A dataset of 627 local sequencing results from clinical MTB isolates originating in Syria (n¼56), 15 China (n¼207), 16 Bangladesh (n ¼207) 17 and the Republic of Korea (n ¼ 157) 18 was analysed. Each strain was previously locally sequenced to identify mutations in the RRDR of the rpoB gene. 15 -18 Only rpoB mutations that were found to reduce rifampicin susceptibility in Salmonella were defined as Rif R mutations. A total of 647 Rif R mutations were identified within this dataset consisting of 34 different amino acid changes. For each of the 647 mutations it was determined whether the mutation was the sole Rif R mutation within that isolate or if it was accompanied by additional Rif R mutations. The mutations were grouped according to the rifampicin MIC level they conferred in Salmonella and for each group the fraction of Rif R mutations that was accompanied by additional Rif R mutations was calculated (Table S2) .
Analysis of clinical MTB data to determine the frequency of additional RNAP mutations
A dataset of 257 rifampicin-susceptible and 108 Rif R clinical isolates was analysed to determine the frequency of additional, non-Rif R mutations in RNAP genes. Each of these 365 isolates was previously whole-genome sequenced and mutations were identified. 19 -21 The 108 Rif R isolates were analysed for two types of mutations: (i) Rif R mutations (rpoB mutations that reduce rifampicin susceptibility in Salmonella); and (ii) secondary, putative compensatory, mutations (non-Rif R mutations in the RNAP genes rpoA, rpoB and rpoC that are found in Rif R isolates, but not in rifampicin-susceptible isolates) (Table S3) .
Statistical analysis
Regression analysis to test correlations was performed using R, version 2.15.2.
Results and discussion
One-hundred and twenty-two distinct mutations reduce susceptibility to rifampicin in Salmonella Typhimurium A total of 122 distinct mutations that reduce susceptibility to rifampicin were constructed in rpoB and moved into an isogenic Salmonella Typhimurium 14028s background. An additional 17 mutations in rpoB that were previously described to be putative Rif R mutations in MTB or in Escherichia coli did not grow under the selective conditions (Table S4 ). The confirmed Rif R mutations consist of 78 amino acid substitutions, 4 duplications and 40 deletions, of which the majority (86%) are located inside the RRDR (Figure 1 ). The other mutations are found in cluster N (4%) and cluster II (10%) (Table S5 and Figure 1 ). Rifampicin MICs associated with the different mutations ranged from 50 to .3000 mg/L (MIC for WT¼12 mg/L), while the associated fitness values ranged between 25% and 105% relative to the fitness of the drugsusceptible WT (Table S5 ).
The fitness cost of Rif R mutations does not vary between different Salmonella strains
To test the robustness of the measured fitness costs associated with the Rif R mutations, a subset of the mutations was moved into the non-virulent Salmonella Typhimurium strain LT2 and into the Salmonella Saintpaul strain CDC B1605. The fitness cost of the resistance mutations in these additional strains showed no significant difference relative to the fitness cost in Salmonella Typhimurium 14028s (Table S6 ). A common theory to explain the strong bias in the frequency of different Rif R mutations found in clinical MTB isolates is that specific Rif R mutations have a low fitness cost or none at all and are therefore more prevalent in clinical samples. 9 Plotting the MICs for the resistant strains versus their respective fitness shows that there is no correlation between the fitness cost measured in Salmonella and the respective frequency in clinical MTB samples (Figure 2) . In contrast, the data suggest that the resistance mutations rpoB H526Y and rpoB S531L, which are found in 65% of clinical MTB isolates, 3 have relatively high fitness costs of 18% and 29% per generation, respectively. Increasing rifampicin concentrations affected the fitness cost of low-level resistance mutations more strongly than the cost of high-level resistance mutations, but even in the presence of 100 mg/L rifampicin, the Rif R mutation rpoB S531L is not among the fittest Rif R mutations (Table S5 and Figure 2 ).
Clinically relevant Rif R mutations have a high MIC
Almost all clinical Rif R MTB isolates have amino acid substitutions at rpoB positions D516, H526 and S531. 3, 5 Each of these mutations individually causes a high MIC of rifampicin (Table S5 ). In MTB isolates carrying one of the high-level resistance mutations there is generally no other Rif R mutation present in rpoB. In some clinical MTB isolates rpoB mutations that individually confer only a low MIC of rifampicin are found. Strikingly, these low-level resistance mutations are almost always found together with a second Rif R mutation in rpoB (Figure 3 ). 15 -18 In addition, the reduction in fitness caused by the presence of rifampicin is not evenly distributed among the different mutants, but is greatest for those with mutations conferring a low level of resistance (Table S5 and Figure 2 ). Taken together, these data strongly suggest that the primary selection pressure on clinical isolates is for a high rifampicin MIC, and that mutations conferring low MICs, when alone, are insufficient to satisfy this selection.
There is a strong correlation between the fitness cost of Rif R mutations in Salmonella Typhimurium and the frequency of putative compensatory mutations in clinical MTB samples Rif R mutations that are commonly found in clinical MTB samples were shown to cause a high fitness cost in Salmonella Typhimurium. Recent studies in Salmonella 13, 22 and M. smegmatis 23 showed that secondary mutations in the RNAP genes can compensate for the fitness cost of Rif R . Additionally, studies in MTB 19, 24 show the presence of similar RNAP mutations in clinical samples. Analysing whole genome sequences of 257 rifampicinsusceptible and 108 Rif R MTB isolates 19 -21 for putative compensatory mutations (non-resistance mutations in the RNAP genes that are found in resistant strains, but not in susceptible strains) shows that there is a strong correlation (R 2 ¼ 0.86, P ¼ 0.0004) between the fitness cost measured as growth rate in Salmonella and the frequency of putative compensatory mutations in clinical MTB isolates (Table S3 and Figure 4) Figure 1 . Distribution of Rif R mutations described in this study. The amino acid sequence and codon numbers of the relevant parts of the rpoB gene in Salmonella Typhimurium are written in the centre. Amino acid substitutions that reduce susceptibility to rifampicin are shown below the sequence. Deletions (white) and insertions (grey) that reduce susceptibility to rifampicin are shown above the sequence. Novel amino acids introduced into the sequence as a consequence of the specific deletions or insertions are written within the respective boxes.
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correlation could also be observed using a different measurement of bacterial fitness. The results show the same correlation (R 2 ¼ 0.74, P ¼ 0.0015) between relative bacterial fitness and frequency of putative compensatory mutations ( Figure S1 and Table S3 ). It is not obvious that the fitness cost of a Rif R mutation in Salmonella needs be equal to the fitness cost of a Rif R mutation in MTB. Spontaneous Rif R mutations were selected in M. smegmatis to test the observed correlation using a model organism that is more similar to MTB. Four of the 10 relevant Rif R mutations were successfully isolated in M. smegmatis and their relative fitness was determined. The same trend (R 2 ¼0.68, P¼ 0.17) can be observed using M. smegmatis fitness as seen using Salmonella fitness ( Figure S1 and Table S3 ), suggesting that these fitness costs could be extrapolated across species boundaries.
Summary and conclusions
In this study we have compared experimental data on the relative fitness and MIC associated with a comprehensive set of Rif R mutations constructed in a model organism, with mutation frequency data obtained from whole-genome sequence analysis of clinical MTB isolates, including the full rpoA, rpoB and rpoC gene sequences in our analysis. Our major finding for the Rif R mutations that are frequently found in MTB isolates is a strong correlation between a high relative fitness cost of the mutation in the isogenic Salmonella strains and a high probability that the mutation is found together with a putative compensatory mutation in clinical MTB isolates (R 2 ¼ 0.86, P¼ 0.0004; Figure 4 ). This correlation also A dataset of 627 clinical MTB isolates that were previously locally sequenced to identify mutations in the RRDR of the rpoB gene was used. 15 -18 rpoB mutations that were found to reduce rifampicin susceptibility in Salmonella were defined as Rif R mutations and for each of the mutations it was determined whether the mutation was the sole Rif R mutation within the isolate or if it was accompanied by additional Rif R mutations. The mutations were grouped according to the rifampicin MIC they confer in Salmonella and for each group the fraction of Rif R mutations that is accompanied by additional Rif R mutations was calculated. The curve represents the correlation between the probabilities of finding secondary Rif R mutations in clinical MTB samples based on the MIC caused by the primary resistance mutation calculated by regression analysis.
Phenotypic characterization of Rif R mutations holds true if competitive fitness cost is used rather than growthrate measurements of fitness (R 2 ¼ 0.74, P ¼ 0.0015; Figure S1 ), and also for the mutants of M. smegmatis analysed. We suggest, based on the correlations between experimental data in the model system and mutation frequencies in MTB isolates, that low initial fitness cost may not be the sole factor that determines the success of Rif R mutations in clinical MTB isolates. Instead clinical success seems to depend on a combination of three factors: (i) a high rifampicin MIC; (ii) a relatively low initial fitness cost; and (iii) the ability to additionally acquire compensatory mutations selected to reduce fitness cost, thus stabilizing the mutation in the population.
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Tables S1 -S6 and Figure S1 are available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/). . Probability of finding putative compensatory mutations in clinical MTB isolates based on the initial fitness cost of the resistance mutation measured in Salmonella Typhimurium. Whole-genome sequences of 257 rifampicin-susceptible and 108 Rif R isolates were used. 19 -21 The 108 Rif R isolates were analysed for two types of mutations: (i) Rif R mutations (rpoB mutations that reduce susceptibility to rifampicin in Salmonella); and (ii) putative compensatory mutations (non-Rif R mutations in the RNAP genes rpoA, rpoB and rpoC that are found in Rif R isolates, but not in rifampicin-susceptible isolates). The curve shows the correlation between the probabilities of finding putative compensatory mutations in clinical MTB isolates based on the initial fitness cost of the resistance mutation measured in Salmonella Typhimurium calculated by regression analysis.
